The Frequency Of Rs2231142 in ABCG2 Among Native Hawaiian nd Pacific Islander Subgroups: Implications for Personalized Rosuvastatin Dosing

References

• Rosuvastatin Oral (Drug Facts and Comparison) online.lexi.com. Wolters Kluwer, (2023).
   Google Scholar
• Bajaj T , GA. Rosuvastatin.StatPearls Publishing (2022). www.ncbi.nlm.nih.gov/books/NBK539883/
   Google Scholar
• Arnett DK , BlumenthalRS , AlbertMAet al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J. Am. Coll. Cardiol.74(10), e177–e232 (2019).
   PubMed Web of Science ®Google Scholar
• Grundy SM , StoneNJ , BaileyALet al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation139(25), e1082–e1143 (2019).
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality . Statin use in U.S. adults doubles (2018). (Accessed 6December2022). www.ahrq.gov/data/infographics/statin-use.html
   Google Scholar
• Cheeley MK , SaseenJJ , AgarwalaAet al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J. Clin. Lipidol.16(4), 361–375 (2022).
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A , Alvarado-CardenasM , Pinal-FernándezIet al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev. Clin. Immunol.14(3), 215–224 (2018).
   PubMed Web of Science ®Google Scholar
• Pulipati VP , DavidsonMH. How I treat statin-associated side effects in an outpatient setting. Future Cardiol.17(7), 1249–1260 (2021).
   PubMed Web of Science ®Google Scholar
• Kanukula R , SalamA , RodgersA , KalemB. Pharmacokinetics of rosuvastatin: a systematic review of randomised controlled trials in healthy adults. Clin. Pharmacokinet.60(2), 165–175 (2021).
   PubMed Web of Science ®Google Scholar
• Hira D , TeradaT. BCRP/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. Biochem. Pharmacol.147, 201–210 (2018).
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM , NiemiM , RamseyLBet al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther.111(5), 1007–1021 (2022).
   PubMed Web of Science ®Google Scholar
• Lee H-K , HuM , LuiSSet al. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics14(11), 1283–1294 (2013).
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I , Casal-DominguezM , MammenAL. Statins: pros and cons. Med. Clin. (Barc.)150(10), 398–402 (2018).
   PubMed Web of Science ®Google Scholar
• Oesterle A , LaufsU , LiaoJK. Pleiotropic effects of statins on the cardiovascular system. Circ. Res.120(1), 229–243 (2017).
   PubMed Web of Science ®Google Scholar
• Murphy C , DeplazesE , CranfieldCG , GarciaA. The role of structure and biophysical properties in the pleiotropic effects of statins. Int. J. Mol. Sci.21(22), 8745 (2020).
   PubMed Web of Science ®Google Scholar
• Bansal AB . HMG-CoA reductase inhibitors. (2022). PMID: 31194369
   Google Scholar
• Luvai A , MbagayaW , HallAS , BarthJH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin. Med. Insights Cardiol.6, 17–33 (2012).
   PubMedGoogle Scholar
• Newman CB , PreissD , TobertJAet al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol.39(2), e38–e81 (2019).
   PubMed Web of Science ®Google Scholar
• Cannon CP . Statin intolerance: how common is it and how do we work with patients to overcome it?Eur. Heart J.43(34), 3224–3226 (2022).
   PubMed Web of Science ®Google Scholar
• US FDA . CRESTOR (rosuvastatin calcium) tablets (2003). (Accessed 1October2022). www.accessdata.fda.gov/drugsatfda_docs/label/2010/021366s016lbl.pdf
   Google Scholar
• Thompson P , PanzaG , ZaleskiA , TaylorB. Statin-associated side effects. J. Am. Coll. Cardiol.67(20), 2395–2410 (2016).
   PubMed Web of Science ®Google Scholar
• Taylor BA , ThompsonPD. Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics15(4), 1006–1017 (2018).
   PubMed Web of Science ®Google Scholar
• Safitri N , AlainaMF , PitalokaDA , AbdulahR. A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management. Drug Healthc. Patient Saf.13, 211–219 (2021).
   PubMed Web of Science ®Google Scholar
• Tournadre A . Statins, myalgia, and rhabdomyolysis. Joint Bone Spine87(1), 37–42 (2020).
   PubMed Web of Science ®Google Scholar
• Taylor BA . Prevalence of SAMS in observational and clinical trials. In: Statin-Associated Muscle Symptoms. ThompsonPD, TaylorBA ( Eds). Springer International Publishing, Cham, Switzerland, 43–50 (2020).
   Google Scholar
• Serban MC , ColantonioLD , ManthripragadaADet al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J. Am. Coll. Cardiol.69(11), 1386–1395 (2017).
   PubMed Web of Science ®Google Scholar
• Climent E , BenaigesD , Pedro-BotetJ. Hydrophilic or lipophilic statins?Front. Cardiovasc. Med.8, 687585 (2021).
   PubMed Web of Science ®Google Scholar
• Hu M , ToKK , MakVW , TomlinsonB. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol.7(1), 49–62 (2011).
   PubMed Web of Science ®Google Scholar
• Lehtisalo M , TaskinenS , TarkiainenEKet al. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Br. J. Clin. Pharmacol.89(1), 242–252 (2023).
   PubMed Web of Science ®Google Scholar
• Bytyçi I , PensonPE , MikhailidisDPet al. Prevalence of statin intolerance: a meta-analysis. Eur. Heart J.43(34), 3213–3223 (2022).
   PubMed Web of Science ®Google Scholar
• Stroes ES , ThompsonPD , CorsiniAet al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J.36(17), 1012–1022 (2015).
   PubMed Web of Science ®Google Scholar
• Bhakta S . Data disaggregation: the case of Asian and Pacific Islander data and the role of health sciences librarians. J. Med. Libr. Assoc.110(1), 133–138 (2022).
   PubMed Web of Science ®Google Scholar
• Morey BN , ChangRC , ThomasKBet al. No equity without data equity: data reporting gaps for Native Hawaiians and Pacific Islanders as structural racism. J. Health Polit. Policy Law47(2), 159–200 (2022).
   PubMed Web of Science ®Google Scholar
• Alghubayshi A , EdelmanA , AlrajehK , RomanY. Genetic assessment of hyperuricemia and gout in Asian, Native Hawaiian, and Pacific Islander subgroups of pregnant women: biospecimens repository cross-sectional study. BMC Rheumatol.6(1), 1 (2022).
   PubMedGoogle Scholar
• Jones N , MarksR , RamirezR , Ríos-VargasM. Census illuminates racial and ethnic composition of the country (2021). www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html
   Google Scholar
• Kaholokula JK , IngCT , LookMA , DelafieldR , SinclairK. Culturally responsive approaches to health promotion for Native Hawaiians and Pacific Islanders. Ann. Hum. Biol.45(3), 249–263 (2018).
   PubMed Web of Science ®Google Scholar
• Office of Minority Health(OMH), US Department of Health and Human Services. Profile: Native Hawaiians/Pacific Islanders 3/1/2022 (2022). https://minorityhealth.hhs.gov/omh/browse.aspxlvl=3&lvlid=65 (Accessed 10October2022).
   Google Scholar
• Doan LN , TakataY , HookerK , Mendez-LuckC , IrvinVL. Trends in cardiovascular disease by Asian American, Native Hawaiian, and Pacific Islander ethnicity, Medicare Health Outcomes Survey 2011–2015. J. Gerontol. A Biol. Sci. Med. Sci.77(2), 299–309 (2022).
   PubMed Web of Science ®Google Scholar
• Liu Y , LvX , XieNet al. Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012–2018). BMC Cardiovasc. Disord.20(1), 201 (2020).
   PubMed Web of Science ®Google Scholar
• Wu HF , HristevaN , ChangJet al. Rosuvastatin pharmacokinetics in Asian and White subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions. J. Pharm. Sci.106(9), 2751–2757 (2017).
   PubMed Web of Science ®Google Scholar
• Shin J-I , FineDM , SangYet al. Association of rosuvastatin use with risk of hematuria and proteinuria. J. Am. Soc. Nephrol.33(9), 1767–1777 (2022).
   PubMed Web of Science ®Google Scholar
• Allikmets R , SchrimlLM , HutchinsonA , Romano-SpicaV , DeanM. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res.58(23), 5337–5339 (1998).
   PubMed Web of Science ®Google Scholar
• Allen JD , van LoevezijnA , LakhaiJMet al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther.1(6), 417–425 (2002).
   PubMed Web of Science ®Google Scholar
• Khunweeraphong N , SzöllősiD , StocknerT , KuchlerK. The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid. Nat. Commun.10(1), 5433 (2019).
   PubMedGoogle Scholar
• National Center for Biotechnology Information . ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) [Homo sapiens (human)] (2022). www.ncbi.nlm.nih.gov/gene/9429
   Google Scholar
• Safar Z , KisE , ErdoF , ZolnerciksJK , KrajcsiP. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin. Drug Metab. Toxicol.15(4), 313–328 (2019).
   PubMed Web of Science ®Google Scholar
• Hanke N , Gómez-MantillaJD , IshiguroN , StopferP , NockV. Physiologically based pharmacokinetic modeling of rosuvastatin to predict transporter-mediated drug–drug interactions. Pharm. Res.38(10), 1645–1661 (2021).
   PubMed Web of Science ®Google Scholar
• Stacy AE , JanssonPJ , RichardsonDR. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol. Pharmacol.84(5), 655–669 (2013).
   PubMed Web of Science ®Google Scholar
• Higashino T , TakadaT , NakaokaHet al. Multiple common and rare variants of ABCG2 cause gout. RMD Open3(2), e000464 (2017).
   PubMed Web of Science ®Google Scholar
• Zattoni IF , KronenbergerT , KitaDHet al. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Chem. Biol. Interact.351, 109718 (2022).
   PubMed Web of Science ®Google Scholar
• Suzuki M , SuzukiH , SugimotoYet al. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem.278(25), 22644–22649 (2003).
   PubMed Web of Science ®Google Scholar
• Hu M , LeeHK , ToKKet al. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. Eur. J. Clin. Pharmacol.72(12), 1471–1478 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang D , DingY , WangXet al. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Eur. J. Clin. Pharmacol.76(7), 939–946 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang X , LiuQ , ZhangHet al. Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab. Mol. Genet. Genomics297(3), 833–841 (2022).
   PubMed Web of Science ®Google Scholar
• Tomlinson B , HuM , LeeVWet al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther.87(5), 558–562 (2010).
   PubMed Web of Science ®Google Scholar
• Fuentes AV , PinedaMD , VenkataKCN. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy (Basel)6(2), 43 (2018).
   PubMedGoogle Scholar
• McBride CL , AkeroydJM , RamseyDJet al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the Department of Veterans Affairs. Vasc. Med.23(3), 232–240 (2018).
   PubMed Web of Science ®Google Scholar
• Robey RW , ToKK , PolgarOet al. ABCG2: a perspective. Adv. Drug Deliv. Rev.61(1), 3–13 (2009).
   PubMed Web of Science ®Google Scholar
• Song Y , LimHH , YeeJ , YoonHY , GwakHS. The association between ABCG2 421C>A (rs2231142) polymorphism and rosuvastatin pharmacokinetics: a systematic review and meta-analysis. Pharmaceutics14(3), 501 (2022).
   PubMed Web of Science ®Google Scholar
• Birmingham BK , BujacSR , ElsbyRet al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur. J. Clin. Pharmacol.71(3), 329–340 (2015).
   PubMed Web of Science ®Google Scholar
• Roman Y , TiirikainenM , Prom-WormleyE. The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clin. Rheumatol.39(8), 2387–2392 (2020).
   PubMed Web of Science ®Google Scholar
• Roman YM , LorK , XiongT , Culhane-PeraK , StrakaRJ. Gout prevalence in the Hmong: a prime example of health disparity and the role of community-based genetic research. Per. Med.18(3), 311–327 (2021).
   PubMed Web of Science ®Google Scholar
• Cunningham F , AllenJE , AllenJet al. Ensembl 2022. Nucleic Acids Res.50(D1), D988–D995 (2021).
   Web of Science ®Google Scholar
• Liao JK . Safety and efficacy of statins in Asians. Am. J. Cardiol.99(3), 410–414 (2007).
   PubMed Web of Science ®Google Scholar
• Alrajeh KY , RomanYM. The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. Per. Med.19(4), 327–339 (2022).
   PubMedGoogle Scholar
• Watanabe LM , SealeLA. Challenging aspects to precise health strategies in Native Hawaiian and other Pacific Islanders using statins. Front. Public Health10, 799731 (2022).
   PubMed Web of Science ®Google Scholar
• Raeisi-Giglou P , JabriA , ShahroriZet al. Disparities in the prescription of statins in the primary care setting: a retrospective observational study. Curr. Probl. Cardiol.47(11), 101329 (2022).
   PubMed Web of Science ®Google Scholar
• Roman YM . Race and precision medicine: is it time for an upgrade?Pharmacogenomics J.19(1), 1–4 (2019).
   PubMed Web of Science ®Google Scholar
• Anderson AN , ChanAR , RomanYM. Pharmacogenomics and clinical cultural competency: pathway to overcome the limitations of race. Pharmacogenomics23(6), 363–370 (2022).
   PubMed Web of Science ®Google Scholar
• Di Sanzo M , CipolloniL , BorroMet al. Clinical applications of personalized medicine: a new paradigm and challenge. Curr. Pharm. Biotechnol.18(3), 194–203 (2017).
   PubMed Web of Science ®Google Scholar
• Roman Y . The United States 2020 Census data: implications for precision medicine and the research landscape. Per. Med.19(1), 5–8 (2022).
   PubMed Web of Science ®Google Scholar
• Bakkum MJ , VerdonkP , ThomasEGet al. A clinical pharmacology and therapeutics teacher’s guide to race-based medicine, inclusivity, and diversity. Clin. Pharmacol. Ther.doi: 10.1002/cpt.2786 (2022) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar